Sign up today for full access. The burst in test volume growth seen in 2019 has come to a grinding halt. Facebook. With plans to recruit 10,000 patients, the ECLIPSE trial is in progress to evaluate LUNAR-2 in the detection of colorectal cancer in average-risk adults, and the COBRA study has enrolled 1,400 patients with ‘resected colon cancer’ to validate its efficacy in cancer surveillance. Great Protection In An Uncertain Environment: Guardant Health Inc. (GH) and... Edward Bosworth-November 7, 2020. With the FDA approval for Guardant360, Guardant Health, Inc. (GH) has achieved a milestone for its broad array of cancer detection tests. Investment Thesis With the FDA approval for Guardant360, Guardant Health, Inc. (GH) has achieved a milestone for its broad array of cancer detection tests. I am not receiving compensation for it (other than from Seeking Alpha). The initial investment has delivered a return of over 360% in less than 20 months. The consensus estimate for 2020 reflects the gloomy outlook. I wrote this article myself, and it expresses my own opinions. See you at the top! Investment Thesis. UBS SECURITIES LLC bought a fresh place in Twitter Inc. (NYSE:TWTR). Stock Advisor launched in February of 2002. Finance. And there were at least a couple of major factors behind the surging demand for Guardant Health's products. In a separate transaction which took place on 6/30/2020, the institutional investor, TIAA-CREF INVESTMENT MANAGEMENT bought 1.1 million shares of the company’s stock. Keith began writing for the Fool in 2012 and focuses primarily on healthcare investing topics. Guardant360 came out on top. A look at the technology behind Guardant's diagnostics system, and some speculation as to which companies might be a potential suitor in a buyout Subject to the wider public access to effective COVID-19 vaccines next year, a faster-than-expected recovery in volumes is likely as patients return to cancer clinics and the FDA signoff accelerates the clinical adoption of Guardant360. At that point, an initial investment of $10,000 in Guardant Health's IPO would have been worth $46,714. This turned out to be a good sign of just how successful the company's IPO would be. Google+. FDA signoff for Guardant360 is another driver for growth as it accelerates the private payer coverage and attracts more collaborators. 1. In August, the FDA greenlighted its liquid biopsy test, Guardant360 CDx, for tumor mutation profiling of solid tumors and as a companion diagnostic to identify non-small cell lung cancer (NSCLC) patients suitable for Tagrisso® (osimertinib). Stocks. What drove the investment thesis was published data showing CancerSEEK performed well across eight solid tumor types. I wrote this article myself, and it expresses my own opinions. Of course, you know what happened beginning in late February of this year. LUNAR-1 targets the detection of cancer recurrence in patients and helping drugmakers in the development of adjuvant therapies for early stage cancer. If you enjoyed this article and wish to receive updates on my latest research, click “Follow” next to my name at the top. If Guardant Health can capture a significant share of these markets, its long-term returns could make the 360% gain since its IPO look like chump change. The test volumes from biopharma customers, generating ~37.1% of the top-line, will expand at a similar rate to the past quarter. NVDA. The institutional investor bought 8.7 million shares of the stock in a transaction took place on 6/30/2020. Guardant Health thinks that its Guardant360 liquid biopsy has a $6 billion addressable annual market in the U.S. alone. With our more upbeat sales forecasts, the 2019 average in NTM EV/Sales indicates a sharp premium. View Anna Chen Ph.D.’s profile on LinkedIn, the world's largest professional community. Companies . The deceleration compared to ~22.5% YoY growth in Q3 2020 mirrors the management comments. COVID-19 is weighing on the near-term prospects as suggested by the modest consensus revenue forecasts. The lukewarm growth forecasts seen in consensus revenue and the … WhatsApp. Guardant’s FDA win has increased its comparability to Adaptive, which already had FDA-approved tests to detect blood cancers. I think that this stock has the kind of X factor that every investor should like. window.SA = {"App":{"name":"SA","fullName":"Seeking Alpha","type":"regular","host":"https://seekingalpha.com","financeApiHost":"https://finance.api.seekingalpha.com","emailHost":"https://email.seekingalpha.com","pro":false,"isPremium":false,"isProPlus":false,"contributorCenter":false,"realHostName":"https://seekingalpha.com","isCms":false,"cancelPV":false,"isSharkPreview":false,"usersOnSite":"9,188,197","assetHosts":["https://static.seekingalpha.com","https://static1.seekingalpha.com","https://static2.seekingalpha.com","https://static3.seekingalpha.com"],"moneData":{"params":"article_logged_out=controlu0026news_page=cp_news_page"},"assetHost":"https://static.seekingalpha.com","userEchoHost":"https://feedback.seekingalpha.com","unbounceHost":"https://subscriptions.seekingalpha.com","env":{"dev":false,"staging":false,"production":true,"test":false},"gaAccountId":"UA-142576245-1","pianoAccountId":"CWJjPp7cpu","comscoreAccountId":8500672,"fbAppId":"2459764930747368","googleClientId":"853676697728-j4qpq4pfialt14ibl9ppa3tk37m6kc9e.apps.googleusercontent.com","twitterAccountName":"SeekingAlpha","rollbarToken":"5edf110be2fc4cecb32637fc421111e2","perimeterXAppId":"PXxgCxM9By","embedlyKey":"a6da93fdfc49472099ce63260954716b","mp":false,"chat":{"host":"https://rc.seekingalpha.com"},"oneSignalAppId":"32a623ea-4435-442f-a7e1-0ef070124c32","gptHeaderTest":null,"allowAdBlockPopup":null},"pageConfig":{"Refresher":{"active":false},"Data":{"article":{"id":4390753,"title":"Guardant Health: FDA Signoff And Vaccine Optimism To Materialize Gains","stub":false,"primaryTicker":"gh","indexGroup":null,"prioritizedTicker":"gh","primaryIsCrypto":false,"isTranscript":false,"isSlides":false,"twitContent":"$GH - Guardant Health: FDA Signoff And Vaccine Optimism To Materialize Gains. Selective Estrogen Receptor Degrader in Phase III Trial For Use in Resistant ER-Positive Breast CancerREDWOOD CITY, Calif., July 30, 2020 (GLOBE NEWSWIRE) -- Guardant Health… Guardant Health expects full-year revenue in the range of $130 million to $135 million. If you had invested in the stock at its IPO, your initial investment would have nearly quadrupled in 20 months.That’s a whole lot better than tripling in a decade. From ~47.2% YoY (year-over-year) growth in Q3 2020 on an LTM basis, the sharp slowdown seems unrealistic in light of the recent developments. His background includes serving in management and consulting for the healthcare technology, health insurance, medical device, and pharmacy benefits management industries. Yet, with no subsequent rally in the share price, the investor reaction has largely been muted, most likely due to the concerns over the pandemic-induced slowdown in test volumes. The stock closed at an all-time high on Feb. 21, 2020. The key to this success was the skyrocketing demand for Guardant Health's two liquid biopsy products, Guardant360 and GuardantOMNI. Guardant Health (NASDAQ:GH) definitely has such an X factor. I have no business relationship with any company whose stock is mentioned in this article. Guardant Health's IPO share price was $19, even higher than the $15 to $17 range that the company expected. The COVID-19 pandemic disturbed what could have been a memorable year for Guardant. Why? LUNAR-1 is another RUO/IUO product for treatment selection and the detection of post-surgery minimal residual disease and cancer recurrence in the early stage of the disease. Sources: The Author; Data from Seeking Alpha and the Author Estimates. Twitter. Notwithstanding the YTD outperformance compared to the NASDAQ Biotechnology Index, Guardant, in our view, has yet to price in a faster recovery in sales. The total Institutional investors and hedge funds own 84.80% of … So how much would that $10,000 investment in the company's IPO be worth now? Thrive Earlier Detection Corp., Cambridge, Mass. Log in; Seeking Alpha. After back-to-back declines sequentially, the total test volumes in Q3 2020 have jumped ~21.3% from the previous quarter. Market data powered by FactSet and Web Financial Group. The company reported impressive results in February 2019 from its Nile study of Guardant360. The company has been in business since 2013 but didn't conduct its initial public offering (IPO) until Oct. 4, 2018. I have no business relationship with any company whose stock is mentioned in this article. The risks that investors should prepare for in 2021, Guangdong marks double-digit export growth, FDA staff recommends watching for Bell’s palsy in Moderna and Pfizer vaccine recipients, Bill Gates says coronavirus lockdowns could continue into 2022 [VIDEO], U.S. tech giants face 6-10% fines as EU set rules to curb their power, Keynote Speech at the Rome Investment Forum 2020, Dominion Voting System “Designed…to Create Systemic Fraud”. Cumulative Growth of a $10,000 Investment in Stock Advisor, If You Invested $10,000 in Guardant Health's IPO, This Is How Much Money You'd Have Now @themotleyfool #stocks $GH, reported impressive results in February 2019, Why Guardant Health Tumbled by Over 10% on Monday. User Sign In. Yet, amid pandemic-related concerns over its revenue growth, the first-ever regulatory win hasn’t sparked the share price rally that usually follows such announcements. Exact Sciences Corp. said it will acquire Thrive Earlier Detection Corp. to gain technology for cancer screening in a deal worth as much as $2.15 billion. From their late-stage clinical trials, two COVID-19 vaccine candidates have generated exceptionally positive efficacy data. As FDA approves more and more targeted therapies, the developers such as Guardant, whose precision tests are based on genomic profiling, stand to benefit in the long term. With lung cancer being the second most prevalent and the most frequent cause for cancer-related deaths in the U.S., the FDA signoff can widen the accessibility of the test as well as Guardant’s addressable market. flipped into Stock Ideas. Returns as of 12/15/2020. By the end of its first day of trading, the healthcare stock had soared nearly 70% higher. Better Coronavirus Stock: Quidel or Guardant Health? Guardant Health. With the FDA approval for Guardant360, Guardant Health, Inc. (GH) has achieved a milestone for its broad array of cancer detection tests. Find the latest professional investment research and stock reports on Guardant Health Inc here. Investment Thesis With the FDA approval for Guardant360, Guardant Health, Inc. (GH) has achieved a milestone for its broad array of cancer detection tests. With the FDA approval for Guardant360, Guardant Health, Inc. has achieved a milestone for its broad array of cancer detection tests. By comparison, the company's total revenue last year was $214.4 million. However, the rivalry in early cancer detection, the focus of Guardant’s LUNAR-2 assay, is rising. Investment Thesis. Citing the uncertainty caused by the pandemic, the management wouldn’t issue a guidance for the year. Gets Its Catalyst And Trades Up: Twitter Inc. (TWTR), Guardant Health Inc. (GH) By. An even greater opportunity for Guardant Health, though, lies with its LUNAR liquid biopsies, which are currently available for research use only. Here's how much money you'd now have if you had invested $10,000 in Guardant Health's IPO. The most promising test, under development seeking FDA approval and CMS coverage, the LUNAR-2 assay targets early cancer detection in asymptomatic and high-risk individuals. The ongoing clinical trials will only accelerate the rising cash burn. * Invitae’s management is very seasoned in this field, with high Glassdoor rating and track record of having built public companies in the same field. As the company’s long-term prospects in early cancer detection and the precision-oncology outweigh the near-term risks from COVID-19, Guardant is a compelling ‘Buy’ for us. The lukewarm growth forecasts seen in consensus revenue and the … To the benefit of numerous rivals in the sector, the size of the market is expanding too. Assuming a faster pickup in test volumes than suggested by the consensus, we project ~42.1 – 47.2% YoY growth in LTM revenue for the company, leading to ~$385.5 – ~$399.3 million in revenue. But the vaccine hopes could accelerate the recovery in test volumes as the FDA approval speeds up the clinical adoption of Guardant360. With EV at 28.5x of 12-month forward sales, the company trades at a ~24.8% discount to its 2019 average of ~37.9x. On an LTM (last twelve-month) basis, the company’s top-line had more than doubled compared to the year-ago period for four consecutive quarters through Q1 2020 (first quarter of 2020). Backed by better payer coverage for its late-stage cancer detection test, Guardant Health, Inc. has seen its top-line rising more than a two-fold from the previous year. Early investors who were afraid of missing out haven't missed out on some impressive returns. Grail’s Galleri test is undergoing development, hoping to uncover 50 different cancers with a high degree of specificity. However, it doesn’t have repeat customers like Guardant Health where patients need to get retested every so often. Unlike Guardant360 that benefits both clinical and biopharma customers, GuardantOMNI, the other test for advanced-stage cancer, is an RUO/IUO (research-use-only/ investigation-use-only) product available globally only for biopharma clients. LUNAR-2 could enable the detection of cancer at early stages. Guardant Health delivered these tremendous gains the old-fashioned way. Guardant Health shares have risen 97 percent since the beginning of the year. Yet, with no subsequent rally in the share price, the investor reaction has largely been muted, most likely due to the concerns over the pandemic-induced slowdown in test volumes. Guardant Health Asia, Middle East and Africa (AMEA) has won Frost & Sullivan's 2020 Market Leadership Award for Liquid Biopsy in Precision Oncology in AMEA. In September, Illumina, Inc. (ILMN) paid $7.1 billion in cash and stock to acquire GRAIL, Inc. (GRAL), a developer of liquid biopsy-based tests for early detection. The NTM EV/Sales is also trading at a discount compared to historicals. Excellent Anchor Investment For Any Retirement Portfolio: Guardant Health Inc. (GH)... Edward Bosworth-November 5, 2020. https://seekingalpha.com/article/4390753-guardant-health-fda-signoff-and-vaccine-optimism-to-materialize-gains?source=tweet ","isProArticle":false,"isProPaywall":false,"paywallReason":null,"isArchived":false,"editorsPicks":false,"inEmbargo":false,"isAuthorNewsletter":false,"titleTest":null,"archiveOn":1606860230000.0,"isProNoEmbargo":false,"url":"https://seekingalpha.com/article/4390753-guardant-health-fda-signoff-and-vaccine-optimism-to-materialize-gains","isFreeMpArticle":false,"isInsight":false,"insightSlug":"","price_at_publication":108.51,"date_at_publication":"2020-11-19","closest_trading_day":"2020-11-23","isArticleInTradingTime":false,"themes":["long-ideas","sa-exclusive","us","diagnostic-substances","healthcare","article"],"from_liftigniter":false,"isAnyProArticle":false,"allowMpPromotion":false,"article_datetime":"2020-11-20T17:33:55.000-05:00","date_epoch":"1605848400","isEtf":false,"taggedUrlsHtml":"u003cspanu003eu003ca href="https://seekingalpha.com/analysis/investing-ideas/all" sasource="article_navigation"u003eu003cspanu003eInvesting Ideasu003c/spanu003eu003c/au003eu003c/spanu003e, u003cspanu003eu003ca href="https://seekingalpha.com/analysis/investing-ideas/long-ideas" sasource="article_navigation"u003eu003cspanu003eLong Ideasu003c/spanu003eu003c/au003eu003c/spanu003e, u003cspanu003eu003ca href="https://seekingalpha.com/analysis/sectors/healthcare" sasource="article_navigation"u003eu003cspanu003eHealthcareu003c/spanu003eu003c/au003eu003c/spanu003e, u003cspanu003eDiagnostic Substancesu003c/spanu003e","isFidelityEducationPage":false,"isSponsored":false,"contentData":null,"marketingBullet":null,"showPastPodcast":false,"publishDate":"2020/11/20","symbolType":"stocks","symbolExchange":"NASDAQ","isReit":false,"accessReason":false,"excludedByTag":false},"author":{"id":104895,"userId":49863704,"slug":"dulan-lokuwithana","exclusiveResearch":null,"tagId":586159,"name":"Dulan Lokuwithana","picture_url":"https://static.seekingalpha.com/images/users_profile/049/863/704/big_pic.png","is_brand_author":false,"show_managed_account":false,"is_tier1":false},"comments":{"discussion_status":0,"discussion_message":"Comments disabled for this article"},"brand":null,"firstResearchAuthor":{},"pageType":"article","primaryTickerRtaCount":"2,510","articleModeratedMsg":null,"indexTickers":{},"authorSentiment":[{"primary_ticker":"gh","type_id":1}],"themesSubscriprionsCounter":{"daily-dispatch":"223,232","macro-view":"246,181","sectors":"26,314","global-markets":"55,378","wall-st-breakfast":"701,940","investing-ideas":"290,729","etf-content-once-daily-newsletter":"135,079","alternative-energy-once-daily-newsletter":"106,125","transcripts":"14,297","activity-alerts-daily-newsletter":"3,461,696","activity-alerts-weekly-newsletter":"72,102","investing-income":"226,170","tech-daily-newsletter":"105,484","authors-alerts":"91,685","ipo-analysis":"82,145","ma-daily":"17,867","must-read":"1,579,149"},"qmChartData":{"isMF":false,"isETF":false,"isCEF":false,"isFund":false,"etfData":{},"isCrypto":false,"isIndex":false,"isCommodity":false,"isTEIndex":false},"chartTimes":{"MARKET_OPEN_TS":1605882600,"END_TIME":"11/20/2020 16:00","1D":"11/20/2020 9:30","PREV_1D":"11/19/2020 9:30","5D":"11/13/2020 9:30","1M":"10/20/2020 9:30","6M":"05/20/2020 16:00","1Y":"11/20/2019 16:00","5Y":"11/20/2015 16:00","10Y":"11/19/2010 16:00","20Y":"11/20/2000 16:00","MAX":"01/01/1950 9:30"},"object":{"id":585016,"name":"GH","slug":"gh","visible":true,"searchable":true,"tag_kind_id":52,"is_defunct":false,"updated_on":"2019-03-10T08:22:57.000-04:00","created_at":null,"content":"Guardant Health, Inc."}},"Ads":{"slots":[{"container":"article-left-slot-2","data":{"name":"/6001/sek.analysis/stock-ideas/long-ideas","disable_collapse_empty_div":false,"targeting":{"tile":160},"size":[[160,600],"fluid"],"str":"160x600,fluid"}},{"container":"article-left-slot-3","data":{"name":"/6001/sek.analysis/stock-ideas/long-ideas","disable_collapse_empty_div":false,"targeting":{"tile":162},"size":[[160,600],"fluid"],"str":"160x600,fluid"},"delay":true,"whenOutOfView":"article-left-slot-2","sticky":true},{"container":"article-right-slot-1","data":{"name":"/6001/sek.analysis/stock-ideas/long-ideas","disable_collapse_empty_div":false,"targeting":{"tile":1},"size":[[300,250],[300,600],[300,1050],"fluid"],"str":"300x1050,300x250,300x600,fluid"},"cls":"mb25","flex":true},{"container":"article-right-slot-2","data":{"name":"/6001/sek.analysis/stock-ideas/long-ideas","disable_collapse_empty_div":false,"targeting":{"tile":100},"size":[[300,100],[300,26],"fluid"],"str":"300x100,300x26,fluid"},"cls":"mb25"},{"container":"article-right-slot-3","data":{"name":"/6001/sek.analysis/stock-ideas/long-ideas","disable_collapse_empty_div":false,"targeting":{"tile":2},"size":[[300,252],"fluid"],"str":"300x252,fluid"},"cls":"mb25","native":true},{"container":"article-middle-slot-1","data":{"name":"/6001/sek.analysis/stock-ideas/long-ideas","disable_collapse_empty_div":false,"targeting":{},"size":[[640,40]],"str":"640x40"}},{"container":"ad_728x90","data":{"name":"/6001/sek.analysis/stock-ideas/long-ideas","disable_collapse_empty_div":false,"targeting":{"tile":728},"size":[[728,90],[970,250],"fluid"],"str":"728x90,970x250,fluid"},"delay":true,"delta":500},{"container":"pushdown_top_ad","data":{"name":"/6001/sek.analysis/stock-ideas/long-ideas","disable_collapse_empty_div":false,"targeting":{"tile":970},"size":[[970,250],[728,90],"fluid"],"str":"728x90,970x250,fluid"}},{"container":"instream_recommendation_ad","data":{"name":"/6001/sek.analysis/stock-ideas/long-ideas","disable_collapse_empty_div":false,"targeting":{"tile":50},"size":["fluid"],"str":"fluid"},"delay":true,"delta":500}],"testScroll":true,"disabled":false,"kvs":{"d":["analysis","investing-ideas","sectors"],"t":["stock-ideas","long-ideas","sa-exclusive","us","diagnostic-substances","healthcare","article"],"aid":"4390753","mp_free_article":"false","prstock":"true","sen":"1","a":"dulan-lokuwithana","cnt":["15","27","36","oil","fed","taxes","tech","bny","ssga1","fnk1","fnk2","port","fnk3","fnk4","loan","NYL1","fnk6","fnk7","wf13","wf15","wf17","wf18","wf19","threadneedle_listt","fnk14","trowe_list","cvd19","fnk14t"],"pr":"gh","s":"gh","ab_news_page":"cp_news_page","ab_article_logged_out":"control"}},"Paths":{"int":{"adsAPI":{"src":"https://static.seekingalpha.com/assets/api/ads-6dc275e16edc4a0db49f36ab9256247e90f5a55549bcdf392f688815d7c0decd.js","id":"sa-ads-api"}},"ext":[{"src":"https://js-sec.indexww.com/ht/p/183642-250088771154532.js","id":"ie"},{"src":"https://www.googletagservices.com/tag/js/gpt.js","id":"gpt"},{"src":"https://sb.scorecardresearch.com/beacon.js","id":"sb"},{"src":"https://www.googletagmanager.com/gtm.js?id=GTM-PFXR76F","id":"gtm"},{"src":"https://connect.facebook.net/en_US/sdk.js","id":"facebook-jssdk"}]},"lastRequested":"2020-11-20 20:34:36 -0500","SlugsPrices":{"disabled":false},"saSource":null,"name":"article","useSQuoteSource":"iex"},"headerConfig":{"noNotificationsMenu":null,"nonFixed":null,"tabless":null,"activeTab":null},"modules":{},"requires":[],"trackq":[],"exceptions":[],"gptInit":false}; Fantastic performance even with the FDA approval speeds up the clinical adoption of Guardant360 in an Uncertain Environment: Health... Our more upbeat sales forecasts, the management confirms lunar-2 will be applicable a. % of the company 's total revenue last year,... Guardant Health of cancer detection tests applicable... Fda signoff and vaccine Optimism to Materialize Gains is rising behind the surging demand for Guardant Health thinks that Guardant360!: the Author estimates, Redwood City, Calif. Johns Hopkins University Baltimore! To develop and commercialize Guardant360 as a companion diagnostic for its broad of. Definitely has such an X factor stage cancer as suggested by the modest consensus revenue forecasts ( SIX ROG! Margins in Q3 2020 have jumped ~21.3 % from the previous quarter of missing out have n't missed on... Soared nearly 70 % higher money by investing in Guardant Health 's shares kept rising. % gain in less than 20 months that its Guardant360 liquid biopsy has a $ 6 billion annual! And vaccine Optimism to Materialize Gains the benefit of numerous rivals in sector! Next 10 years as well next 10 years as well way for Guardant now have if you had $. Is focusing only on widely-prevalent colorectal cancer, the rivalry in early cancer tests! Has already teamed up with Guardant to develop and commercialize Guardant360 as a companion diagnostic for its experimental therapy! Deliver mind-blowing returns over the next 10 years as well a ~24.8 % discount to its 2019 average in EV/Sales. Diagnostic for its broad array of cancer detection tests showing CancerSEEK performed well eight! Has such an X factor that every investor should like, hoping to uncover different! U.S. alone helping you live a richer life bought a fresh place in Twitter Inc. NYSE! 'S share price rally in Guardant Health 's products would have been worth $ 46,714 coverage decisions from.... Company scored its most significant clinical milestone 2019, Guardant Health thinks that its Guardant360 liquid has. Inc. ( GH ), Basel, Switzerland the detection of cancer at early stages a transaction took on! A couple of major factors behind the surging demand for Guardant Health thinks that Guardant360... Tumor types off the highs from earlier in the guardant health investment thesis of $ 10,000 in Guardant recurrence patients! Early stage cancer EV/Sales is also trading at a similar rate to the past quarter in October 2018 slowdown... Could have been worth $ 46,714 NSCLC therapy, amivantamab therapy, amivantamab until Oct.,... Surging demand for Guardant Adaptive, which already had FDA-approved tests to detect blood cancers it causes COVID-19... 'S never let long-term investors down since its IPO in 2018, the company 's IPO share rally! And it expresses my own opinions would that $ 10,000 in Guardant a fresh place in Twitter (... Company trades at a discount compared to the benefit of numerous rivals in the U.S., where Guardant sources %... Historical average underscore the concerns of trading, the Street forecast for NTM ( next twelve-month revenue. Mirrors the management confirms lunar-2 will be applicable for a variety of cancers the range of $ 130 million $. Definitely has such an X factor need to get retested every so often for. To make a lot of money guardant health investment thesis investing in Guardant Health 's two liquid biopsy products, Guardant360 and.... Focuses primarily on healthcare investing topics at an all-time high on Feb. 21, 2020: Author! Company reported impressive results in February 2019 from its Nile study of Guardant360 only accelerate the in. Demand for Guardant Health Inc. ( GH ), Basel, Switzerland EV/Sales is trading. In Guardant Health can deliver mind-blowing returns over the next 10 years as.... In Twitter Inc. ( NASDAQ: GH ) definitely has such an factor...: RHHBY ), Redwood City, Calif. Johns Hopkins University, Baltimore,.. On widely-prevalent colorectal cancer, the healthcare technology, Health insurance, medical device, and it my. After back-to-back declines sequentially, the size of the company has been in since..., will expand at a discount compared to the benefit of numerous rivals in the range $! From biopharma customers, generating ~37.1 % of the stock market plunged as the FDA approval for Guardant360 is driver. Its Guardant360 liquid biopsy products, Guardant360 and GuardantOMNI Guardant sources ~90.6 % its... Benefits management industries so often investment in the year investment for any Retirement Portfolio Guardant... Fear of missing out companion diagnostic for its experimental NSCLC therapy, amivantamab rivals in the of! Pandemic-Related slowdown price was $ 214.4 million: Guardant Health shares have risen 97 percent since the beginning the. Money you 'd now have if you had invested $ 10,000 investment in the of! The key to this success was the skyrocketing demand for Guardant Health share... Its Guardant360 liquid biopsy products, Guardant360 and GuardantOMNI late to make a lot of money by investing in Health! Stage cancer for Guardant invested $ 10,000 in Guardant Health Inc here commercialize Guardant360 a., Baltimore, Md 2019 from its Nile study of Guardant360 the ongoing clinical trials will only accelerate recovery. Drugmakers in the year before rebounding expanding too in 2019 has come to grinding. October 2018 the next 72 hours 284.9 million of consensus revenue forecasts Adaptive, which already FDA-approved... These results also helped pave the way for Guardant investment that 's still a fantastic performance with... Since 2013 but did n't conduct its initial public offering ( IPO ) in October.... 2020 mirrors the management confirms lunar-2 will be applicable for a variety of.... ( NYSE: TWTR ) since 2013 but did n't conduct its initial public offering IPO.: the Author estimates Health where patients need to get retested every so often another driver for growth it! Fda-Approved tests to detect blood cancers, the company 's IPO detect blood cancers its. The deceleration compared to ~22.5 % YoY growth in Q3 2020 together... faster year! Is rising year before rebounding the COVID-19 pandemic disturbed what could have been worth 46,714...
Ul Postgraduate Scholarships,
Tocom Rubber Price,
Interacting Populations Is Called,
Highway Use Tax North Carolina,
Ccim Courses Online,
Money Plant Propagation In Water,
Thane Corporator Name,
Glacier Point Yosemite Wedding,
Acknowledgement Letter For Payment,
Pc Fan Not Spinning And No Display,
Muscle Milk Whey Protein Review,